Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease

• Protocol code: NN9500-7730
• EudraCT code: No aplica
• Research group: Liver Diseases
• Service: Hepatology
• Principal investigator:  Ventura Cots, Meritxell
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase II
• Status: Recruiting volunteers

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect ofEDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults andAdolescents with Becker Muscular Dystrophy

• Protocol code: EDG-5506-201
• EudraCT code: No aplica
• Research group: Peripheral Nervous System
• Service: Neurology
• Principal investigator:  Juntas Morales, Raul
• Pathology: Malalties del sistema nerviós
• Phase: Fase II
• Status: Recruiting volunteers

Estudio de extensión, abierto de 52 semanas para evaluar la pimavanserina en niños y adolescentes con irritabilidad asociada al trastorno del espectro autista (TEA)

• Protocol code: ACP-103-070
• EudraCT code: 2021-005388-32
• Research group: Psychiatry, Mental Health and Addictions
• Service: Psychiatry
• Principal investigator:  Gisbert Gustemps, Laura
• Pathology: Malalties del sistema nerviós
• Phase: Fase II
• Status: Recruiting volunteers

Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de MK-0616 para reducir las complicaciones cardiovasculares graves en participantes con riesgo cardiovascular elevado.

• Protocol code: MK-0616-015
• EudraCT code: No aplica
• Research group: Cardiovascular Diseases
• Service: Cardiology
• Principal investigator:  Lozano Torres, Jordi
• Pathology: Malalties del sistema circulatori
• Phase: Fase III
• Status: Recruiting volunteers